Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Allosteris

Financiado

Allosteric modulation of immune checkpoint complexes as a new mode of therapeuti...

Allosteric modulation of immune checkpoint complexes as a new mode of therapeutic intervention in immunotherapy The fastidious balance of our immune system to fight infections or cancer while avoiding autoimmune reactions is regulated by coinhibitory and co-stimulatory immune checkpoint complexes (ICCs), which have become major drug targets... ver más

31/05/2029

VLAAMS INSTITUUT...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-22

ERC-2023-ADG: ERC ADVANCED GRANTS Scope:Objectives

I+D

Cerrada hace 1 año

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

VLAAMS INSTITUUT BIOTECHNOL...

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

INCEPTOR Investigate the mode of action ofInvestigate the mode of act... 192K€ Cerrado

ImmuneSynapsEngagers Immune Synapse Engagement as a Novel Approach for Cancer Imm... 2M€ Cerrado

ImmunoChip Nano-assisted digitalizing of cancer phenotyping for immunot... 2M€ Cerrado

NTasePro NTase Products and Cyclic Nucleotide Signalling 2M€ Cerrado

iReceptor Plus ARCHITECTURE AND TOOLS FOR THE QUERY OF ANTIBODY AND T CELL... 9M€ Cerrado

MIMIC Molecular mimicry as a key parameter shaping T cell immunity 2M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2024-05-22
Fecha Fin: 2029-05-31

Líder del proyecto

VIB VZW No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto The fastidious balance of our immune system to fight infections or cancer while avoiding autoimmune reactions is regulated by coinhibitory and co-stimulatory immune checkpoint complexes (ICCs), which have become major drug targets. We witness the skyrocketing progression in cancer immunotherapy with antibodies that block inhibitory ICCs whereas Abs that block stimulatory ICCs are in clinical trials for treating autoimmune diseases. Surprisingly, but likely fuelled by the most obvious focus on IC inhibitors, the field largely ignored that ICCs are genuine transmembrane receptors that transmit signals upon binding of an extracellular protein ligand. This leaves unexplored modes of therapeutic intervention that I will uncover by validating Nanobodies (Nbs) as first-in-class modulators of signaling pathways associated with immune receptors in a unique, previously unexplored fashion. By applying innovative immunization and bio-selection techniques and building on POC data, I will deliver Nbs for representative ICCs to demonstrate the efficacy and selectivity of these Nbs in preclinical models of various inflammatory conditions, focusing on cancer and autoimmune diseases. We will deliver novel therapeutics agents which may outperform current inhibitor-based immunotherapies that trigger a magnitude of side effects. In this regard, the Nbs will exert their therapeutic effect through a distinctive mode of action that will ensure patient safety, even in the event of an overdose.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores